Location History:
- Philadelphia, PA (US) (1998 - 2024)
- Bryn Mawr, PA (US) (2014 - 2024)
Company Filing History:
13 out of 64 
9 out of 1,267 
2 out of 3,688 
Years Active: 1998-2025
Title: Wafik S El-Deiry: Innovator in Cancer Research
Introduction: Wafik S El-Deiry is a prominent figure in the field of cancer research located in Philadelphia, PA. With 22 patents to his name, he has made significant contributions to understanding and treating various cancers, focusing particularly on mechanisms involving EGFR-related and NTRK-related cancers.
Latest Patents: Among his latest patents are groundbreaking methodologies for identifying subjects with cancer that may be susceptible to specific therapeutic agents. One notable patent discusses frequent EGFR and NTRK somatic mutations in colorectal cancer with microsatellite instability. This patent outlines methods geared towards recognizing patients who could benefit from targeted treatments. Another significant patent involves the upregulation of the miR-3132 in the TRAIL pathway, which enhances apoptotic activity in cancer cells. This innovation proposes compositions that utilize miR-3132 alongside pharmaceutical agents to activate the TRAIL signaling pathway as a means of cancer treatment.
Career Highlights: Throughout his career, Wafik S El-Deiry has collaborated with leading research institutions, including the Institute for Cancer Research and the Penn State Research Foundation. His work has not only advanced the scientific understanding of cancer but has also facilitated the development of novel treatment modalities.
Collaborations: El-Deiry has worked alongside esteemed colleagues such as Gen Sheng Wu and Joshua E Allen. These collaborations have played a crucial role in driving forward their shared mission of improving cancer therapies and patient outcomes.
Conclusion: Wafik S El-Deiry continues to be a pivotal force in cancer research through his innovative patents and collaborative work with other experts in the field. His efforts in identifying susceptibility to cancer treatments remain vital for the advancement of personalized medicine in oncology.